Papillary renal neoplasm with reverse polarity may be a novel renal cell tumor entity with low malignant potential.
KRAS
Neoplasm, renal cell
Oncocyte
Papillary
Reverse polarity
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
10
12
2021
accepted:
11
06
2022
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
This study retrospectively investigated the morphological, immunohistochemical and molecular genetic features of papillary renal neoplasm with reverse polarity (PRNRP), a recently described renal tumor. Eleven cases of PRNRP were collected, and 16 cases of type I and 9 cases of type II papillary renal cell carcinoma were included as a control series. Pathological features were evaluated based on HE staining and immunohistochemistry. KRAS exon 2 and BRAF V600E mutations were detected by Real-time PCR and Sanger sequencing. Fluorescence in situ hybridization was conducted for identification of chromosomal abnormalities. Hemosiderin deposition was found in a small amount of tumor cells in 6 cases. Multifocal or patchy necrosis (5/11), small focal invasion of the pseudocapsules or renal parenchyma (6/11), and breakthrough of renal capsule with nerve invasion (1/11) were revealed, inconsistent with the previous view that the tumor lacks necrosis and intercellular hemosiderin. Immunohistochemical staining (diffusely positive for CK7 and GATA3, negative for CD117 and vimentin, and negative to weakly positive for P504S) and high frequency of KRAS mutations in exon 2 (9/10) supported the identification and inclusion of our cases. Chromosome 7 trisomy (1/7), chromosome 17 trisomy (0/7) and chromosome Y deletion (0/5 male patients) were seldom detected in this tumor. All patients were alive without metastasis or recurrence at the end of the follow-up. Our findings may highlight the possibility of a low malignant potential of this emerging entity. We suggest that the tumor be classified as a novel renal cell tumor subtype independent of papillary renal cell carcinoma.
Identifiants
pubmed: 36002896
doi: 10.1186/s13000-022-01235-2
pii: 10.1186/s13000-022-01235-2
pmc: PMC9404576
doi:
Substances chimiques
Biomarkers, Tumor
0
Hemosiderin
9011-92-1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Informations de copyright
© 2022. The Author(s).
Références
Development. 2006 Jan;133(1):53-61
pubmed: 16319112
Am J Surg Pathol. 2019 Aug;43(8):1099-1111
pubmed: 31135486
Hum Pathol. 2008 Jan;39(1):96-101
pubmed: 17949780
Mod Pathol. 2020 Jun;33(6):1157-1164
pubmed: 31534204
Mod Pathol. 2020 Apr;33(4):690-699
pubmed: 31953522
Am J Surg Pathol. 2005 Dec;29(12):1576-81
pubmed: 16327429
Gastroenterology. 1993 Apr;104(4):1044-8
pubmed: 8462792
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Histopathology. 2020 Jun;76(7):1070-1083
pubmed: 31997427
Am J Surg Pathol. 2004 Jan;28(1):69-76
pubmed: 14707866
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Am J Surg Pathol. 2016 Jul;40(7):865-75
pubmed: 26900816
Mod Pathol. 1997 Jun;10(6):537-44
pubmed: 9195569
Am J Surg Pathol. 2000 Feb;24(2):203-10
pubmed: 10680888
Nature. 2000 Jul 27;406(6794):419-22
pubmed: 10935639
Int J Surg Pathol. 2020 Oct;28(7):728-734
pubmed: 32403965
Pathol Int. 2009 Mar;59(3):137-46
pubmed: 19261090
Am J Surg Pathol. 2001 Dec;25(12):1485-92
pubmed: 11717537
Virchows Arch. 2003 Apr;442(4):336-42
pubmed: 12684768
Hum Pathol. 2021 Jun;112:48-58
pubmed: 33811832
Am J Surg Pathol. 2017 Dec;41(12):1618-1629
pubmed: 28984673
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Am J Surg Pathol. 2013 Oct;37(10):1490-504
pubmed: 24025520
Am J Surg Pathol. 2014 Dec;38(12):1588-602
pubmed: 25025441